Location History:
- Parkville, AU (2021)
- Melbourne, AU (2023)
Company Filing History:
Years Active: 2021-2023
Title: Catherine Owczarek: Innovator in CD131 Binding Proteins
Introduction
Catherine Owczarek is a prominent inventor based in Parkville, Australia. She has made significant contributions to the field of biotechnology, particularly in the development of CD131 binding proteins. With a total of 2 patents to her name, her work has the potential to impact therapeutic approaches in immunology.
Latest Patents
Catherine's latest patents focus on CD131 binding proteins and their applications. The first patent describes a CD131-binding protein that comprises an antigen binding domain of an antibody. This domain specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5, and granulocyte-macrophage colony stimulating factor (GM-CSF). The second patent reiterates this innovative approach, emphasizing the importance of these proteins in therapeutic uses.
Career Highlights
Catherine Owczarek is associated with CSL Limited, a leading global biotechnology company. Her work at CSL Limited has allowed her to explore and develop groundbreaking solutions in the field of immunology. Her dedication to research and innovation has positioned her as a key figure in her area of expertise.
Collaborations
Catherine has collaborated with notable colleagues, including Nicholas Wilson and Matthew Hardy. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in biotechnology.
Conclusion
Catherine Owczarek's contributions to the field of biotechnology, particularly through her patents on CD131 binding proteins, highlight her role as an influential inventor. Her work continues to pave the way for advancements in therapeutic applications, showcasing the importance of innovation in science.